For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Modernatx, Inc.

USPTO Granted Patents = 247

% Expired Patents = 0.4

EPO Patents = 57

Trademarks = 27

Forward Citations = 4,041

Loading Chart...

Loading Chart...

193 inventors (with patents filed for the assignee):

Kerry Benenato (58 out of 60 patents)

Giuseppe Ciaramella (56 out of 57 patents)

Stephen G Hoge (53 out of 62 patents)

4. Vladimir Presnyak (39 out of 42 patents)

5. Ellalahewage Sathyajith Kumarasinghe (37 out of 38 patents)

6. Iain McFadyen (31 out of 31 patents)

7. Sunny Himansu (29 out of 30 patents)

8. Joshua P Frederick (27 out of 27 patents)

9. Sayda Mahgoub Elbashir (26 out of 57 patents)

10. Ailin Bai (22 out of 28 patents)

11. Stephane Bancel (22 out of 31 patents)

12. Eric Yi-Chun Huang (21 out of 21 patents)

13. Antonin De Fougerolles (21 out of 21 patents)

14. Tirtha Chakraborty (20 out of 45 patents)

15. Justin Guild (19 out of 22 patents)

Core Competencies:

Nucleic Acid Vaccines

Lipid Nanoparticles

mRNA Quantification

Therapeutic Agents

RNA Formulations

Intracellular Delivery

Modified Nucleosides

Vaccine Development

Polynucleotides

RNA Polymerase Variants

Therapeutic Administration

Intravenous Therapeutics

247 patents: Sort by Forward Citations

1. 12752001 - MUTANT INFLUENZA B/VICTORIA LINEAGE VIRUS HEMAGGLUTININ PROTEINS (2026-10-06),

2. 12741019 - VARIANT STRAIN-BASED CORONAVIRUS VACCINES (2026-09-22),

3. 12740943 - Headgroup lipid compounds and compositions for intracellular delivery of therapeutic agents (2026-09-22),

4. 12691177 - Stabilized formulations (2026-07-28),

5. 12685785 - POLYNUCLEOTIDES ENCODING PROPIONYL-COA CARBOXYLASE ALPHA AND BETA SUBUNITS FOR THE TREATMENT OF PROPIONIC ACIDEMIA (2026-07-21),

6. 12644102 - POLYNUCLEOTIDES ENCODING BRANCHED-CHAIN ALPHA-KETOACID DEHYDROGENASE COMPLEX E1-ALPHA, E1-BETA, AND E2 SUBUNITS FOR THE TREATMENT OF MAPLE SYRUP URINE DISEASE (2026-06-02),

7. 12629412 - BETACORONAVIRUS mRNA VACCINES (2026-05-19),

8. 12622960 - VARICELLA ZOSTER VIRUS (VZV) VACCINE (2026-05-12),

9. D1125545 - Syringe cap wrench (2026-05-05),

10. 12595226 - Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents (2026-04-07),

11. 12552738 - Crystal forms of amino lipids (2026-02-17),

12. 12529047 - mRNA quantification methods (2026-01-20),

13. 12521577 - BETACORONAVIRUS RNA VACCINES (2026-01-13),

14. 12508278 - Lipid nanoparticle compositions and methods of formulating the same (2025-12-30),

15. 12502431 - DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS (2025-12-23),

Company Overview

Modernatx, Inc., based in Cambridge, MA, specializes in the development of nucleic acid vaccines, leveraging advanced technologies in lipid nanoparticles and RNA formulations. The company focuses on innovative therapeutic agents that enhance intracellular delivery and mRNA quantification, contributing significantly to vaccine development. By harnessing modified nucleosides, Modernatx aims to address various health challenges through cutting-edge research in the field of nucleic acid therapeutics.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

247 Patents

#14 in Cambridge, MA

#105 in Massachusetts

#1,735 in US

#3,524 in the World

Cambridge, MA, United States of America

Modernatx, Inc.

Forward Citations = 4,041

193 inventors:

Kerry Benenato (58 out of 60 patents)

Giuseppe Ciaramella (56 out of 57 patents)

Stephen G Hoge (53 out of 62 patents)

4. Vladimir Presnyak (39 out of 42 patents)

5. Ellalahewage Sathyajith Kumarasinghe (37 out of 38 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Modernatx, Inc.. Retrieved from https://idiyas.com/company/modernatx

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…